Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, University of Milan, Milan, Italy.
Thromb Haemost. 2010 Jun;103(6):1136-44. doi: 10.1160/TH09-12-0873. Epub 2010 Mar 29.
Venous thrombosis typically involves the lower extremity circulation. Rarely, it can occur in the cerebral or splanchnic veins and these are the most frightening manifestations because of their high mortality rate. A third site of rare venous thrombosis is the deep system of the upper extremities that, as for the lower extremity, can be complicated by pulmonary embolism and post-thrombotic syndrome. The authors conducted a narrative review focused on clinical manifestations, risk factors, and treatment of rare venous thromboses. Local risk factors such as infections or cancer are frequent in thrombosis of cerebral or portal veins. Upper extremity deep-vein thrombosis is mostly due to local risk factors (catheter- or effort-related). Common systemic risk factors for rare venous thromboses are inherited thrombophilia and oral contraceptive use; chronic myeloproliferative neoplasms are closely associated with splanchnic vein thrombosis. In the acute phase rare venous thromboses should be treated conventionally with low-molecular-weight heparin. Use of local or systemic fibrinolysis should be considered in the case of clinical deterioration in spite of adequate anticoagulation. Anticoagulation with vitamin K-antagonists is recommended for 3-6 months after a first episode of rare venous thrombosis. Indefinite anticoagulation is recommended for Budd-Chiari syndrome, recurrent thrombosis or unprovoked thrombosis and permanent risk factors. In conclusion, the progresses made in the last couple of decades in diagnostic imaging and the broadened knowledge of thrombophilic abnormalities improved the recognition of rare venous thromboses and the understanding of pathogenic mechanisms. However, the recommendations for treatment mainly derive from observational studies.
静脉血栓形成通常涉及下肢循环。很少见的情况下,它也可能发生在脑静脉或内脏静脉中,由于其高死亡率,这些是最可怕的表现。静脉血栓形成的第三个罕见部位是上肢深部系统,与下肢一样,它可能并发肺栓塞和血栓后综合征。作者进行了一项叙述性综述,重点关注罕见静脉血栓形成的临床表现、危险因素和治疗。局部危险因素,如感染或癌症,在脑静脉或门静脉血栓形成中很常见。上肢深静脉血栓形成主要是由于局部危险因素(导管或用力相关)。罕见静脉血栓形成的常见系统性危险因素包括遗传性血栓形成倾向和口服避孕药;慢性骨髓增生性肿瘤与内脏静脉血栓形成密切相关。在急性期,应采用低分子肝素常规治疗罕见静脉血栓形成。尽管抗凝充分,但如果临床恶化,应考虑局部或全身溶栓。对于首次罕见静脉血栓形成后,建议使用维生素 K 拮抗剂进行 3-6 个月的抗凝治疗。对于布加综合征、复发性血栓形成或无诱因性血栓形成以及永久性危险因素,建议无限期抗凝。总之,过去几十年在诊断成像方面的进展和对血栓形成异常的广泛了解,提高了对罕见静脉血栓形成的认识和对发病机制的理解。然而,治疗建议主要来自观察性研究。